Human FGF-21 Antibody

Recombinant Monoclonal Antibody..
  
  • Species Reactivity
    Human
  • Specificity
    Detects human FGF-21 in direct ELISAs.
  • Source
    Recombinant Monoclonal Goat IgG2B Clone # 40020A
  • Purification
    Protein A or G purified from cell culture supernatant
  • Immunogen
    E. coli-derived recombinant human FGF-21
    His29-Ser209
    Accession # Q9NSA1
  • Formulation
    Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
  • Endotoxin Level
    <0.10 EU per 1 μg of the antibody by the LAL method.
  • Label
    Unconjugated
Applications
  •  
    Recommended
    Concentration
    Sample
  • Neutralization
    Measured by its ability to neutralize FGF-21-induced proliferation in BaF3 mouse pro-B cell line transfected with human FGF-RIIIc. The Neutralization Dose (ND50) is typically 0.5-3 μg/mL in the presence of Recombinant Mouse Klotho beta.
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Data Examples
Cell Proliferation Induced by FGF-21 and Neutralization by Human FGF-21 Antibody. In the presence of Recombinant Mouse Klotho beta (Catalog # 2619-KB), Recombinant Human FGF-21 (Catalog # 2539-FG) stimulates proliferation in the BaF3 mouse pro-B cell line transfected with human FGF-RIIIc in a dose-dependent manner (orange line). Under these conditions, proliferation elicited by Recombinant Human FGF-21 (500 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human FGF-21 Mononclonal Antibody (MAB25373). The ND50 is typically 0.5-3 μg/mL.
Preparation and Storage
  • Shipping
    The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
  • Stability & Storage
    Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
    • 12 months from date of receipt, -20 to -70 °C as supplied.
    • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
    • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: FGF-21

Fibroblast growth factor 21 (FGF-21) is a member of the FGF gene family, which currently contains 22 human members. Based on its structure, it is further classified as an FGF19 subfamily member. This subfamily includes FGF-19, -21, and -23. Like all other FGF subfamilies, FGF-19 subfamily members contain a 120 amino acid (aa) core FGF domain that exhibits a beta -trefoil structure (1, 2). Unlike other FGF subfamilies, FGF-19 subfamily members apparently exhibit poor binding to ECM, resulting in highly diffusible molecules (3). The c-DNA for FGF-21 predicts a 209 aa polypeptide that contains a 28 aa signal sequence and a 181 aa mature region (4). Notably, FGF-21, as well as FGF-19 show limited binding to heparin (4). One potential alternate splice form has been reported. It shows a 43 aa substitution for the
C-terminal 12 aa of the standard form (5). Mature human FGF-21 shows 81% aa identity to mouse FGF-21, and is known to be active on mouse cells (4, 6).
The FGF-19 subfamily is considered endocrine in nature. All three subfamily members impact some aspect of metabolism, all three are induced by a nuclear receptor heterodimer that includes RXR, and all three utilize Klotho family members for signal transduction (7, 8, 9). FGF-21 is produced by hepatocytes in response to free fatty acid (FFA) stimulation of a PPARa/RXR dimeric complex (3, 7, 10, 11). This situation occurs clinically during starvation, or following the ingestion of a
high-fat/low-carbohydrate diet. Upon FGF-21 secretion, white adipose tissue is induced to release FFAs from triglyceride stores. Once FFAs reach hepatocytes, they are oxidized and reduced to acetyl-CoA. The acetyl-CoA is recombined into 4-carbon ketone bodies (acetoacetate and beta -hydroxybutyrate), released, and transported to peripheral tissues for TCA processing and energy generation (11, 12).

  • References:
    1. Itoh, N. and D.M. Ornitz (2004) Trends Genet. 20:563.
    2. Mohammadi, M. et al. (2005) Cytokine Growth Factor Rev. 16:107.
    3. Huang, X. et al. (2006) Mol. Carcinog. 45:934.
    4. Nishimura, T. et al. (2000) Biochim. Biophys. Acta 1492:203.
    5. GenBank Accession #: EAW52401 (2006).
    6. Ford, A.M. et al. (2005) J. Clin. Invest. 115:1627.
    7. Moore, D. D. (2007) Science 316:1436.
    8. Ogawa, Y. et al. (2007) Proc. Natl. Acad. Sci. USA 104:7432.
    9. Kurosu, H. et. al. (2007) J. Biol. Chem. 282:26687.
    10. Lundasen, T. et al. (2007) Biochem. Biophys. Res. Commun. 360:437.
    11. Badman, M.K. et al. (2007) Cell Metab. 5:426.
    12. Inagaki, T. et al. (2007) Cell Metab. 5:415.
  • Long Name:
    Fibroblast Growth Factor 21
  • Entrez Gene IDs:
    26291 (Human); 56636 (Mouse)
  • Alternate Names:
    FGF21; FGF-21; fibroblast growth factor 21
Related Research Areas

Have you used Human FGF-21 Antibody?

Submit a review and receive a $25 amazon gift card if you include an image - $10 Amazon card for reviews without an image. Limited to verified customers in USA, Canada and Europe.

Order Details

Contact Information

Certificate of Analysis Lookup

The document you requested is not available online. Please enter the Catalog Number and Lot Number below to have a document emailed to you at the address provided

Certificate of Analysis Lookup

Research Areas of Interest
R&D Systems Guarantee

Feedback

Customer Information